Gilead Sciences to Present at the Cowen & Company 33rd Annual Health Care Conference on Monday, Marc
Gilead Sciences to Present at the Cowen & Company 33rdAnnual Health Care Conference on Monday, March 4
Webcast Available Through Gilead Corporate Website
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (NAS: GILD) today announced that its corporate presentation will be webcast from the Cowen and Company 33rd Annual Health Care Conference in Boston.
John C. Martin, PhD, Gilead's Chairman and Chief Executive Officer, will provide an overview of the company at the Cowen conference on Monday, March 4 at 1:30 p.m. Eastern Time.
To access the live webcast or a replay via the internet log on to www.gilead.com. Please connect to the company's website at least 15 minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary to listen to the webcast. The replay will be available for 14 days following the presentation.
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific.
For more information on Gilead Sciences, please visitwww.gilead.comor call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).
Gilead Sciences, Inc.
Patrick O'Brien, 650-522-1936
KEYWORDS: United States North America California Massachusetts
The article Gilead Sciences to Present at the Cowen & Company 33rd Annual Health Care Conference on Monday, March 4 originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.